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Abstract 
Platelet signalling responses to single agonists have been identified previously. However a 
model of the total platelet signalling network is still lacking. In order to gain insights into this 
network, we explored the effects of a range of platelet-function inhibitors in two independent 
assays of platelet function, namely fibrinogen binding and ADP secretion. In this study, we 
targeted the intracellular signalling molecules Syk and PI3K, the prostaglandin synthesis 
enzyme COX, surface receptors for TxA2 and ADP (P2Y1 and P2Y12) and the integrin cell 
adhesion molecule, αIIbβ3. We demonstrate that the platelet responses of fibrinogen binding 
and secretion can be differentially affected by the individual inhibitors permitting the 
generation of a model delineating novel regulatory links in the platelet signal network. 
Importantly, the model illustrates the interconnections among portions that are traditionally 
studied as separate modules, promoting a more integrated view of the platelet. 
 
Abbreviations:  
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CRP: Collagen Related Peptide 
GPVI: Glycoprotein VI  
Syk: Spleen Tyrosine Kinase  
PI3K: Phosphoinositide 3 kinase 
COX: Cyclooxygenase 
TxA2R: Thromboxane A2 Receptor,  
TRAP: Thrombin Receptor Activating Peptide 
PLA2: phospholipase A2 
 
1. Introduction 
Platelets play a critical role in haemostasis by monitoring the integrity of blood vessels. 
Following adhesion to exposed extracellular-matrix proteins, platelets activate, secrete, and 
aggregate on a damaged endothelium1. Platelet activation proceeds through a poorly 
understood sequence of signalling events which culminates in the “inside-out” activation of 
the integrin αIIbβ3 cell adhesion molecule2, regardless of the agonist. The heterodimeric 
αIIbβ3 cell adhesion molecule is the most abundant integrin on platelet surface, with about 
80000 copies per cell3-4  and acts as a fibrinogen receptor5. The common downstream effector 
of integrin activation is talin, upon which all the intracellular signalling routes converge 
irrespective of the agonist that initiated them6. It is known that talin, once its auto-inhibition is 
relieved, inserts itself between the integrin cytoplasmic tails and binds to the β-tail, thereby 
causing the extracellular portions to undergo a conformational switch that increases the 
affinity for fibrinogen6-7. Fibrinogen binding in turn elicits a signalling cascade (outside-in 
signalling) that is required for a full irreversible aggregation response and is therefore 
considered a key step in platelet activation8.  
Among post-activation events, ADP secretion and thromboxane (Tx)A2 production are of 
undisputed importance since both provide short-distance signals for local amplification of the 
haemostatic response9-10. ADP signalling in platelets is important for sustained aggregation, 
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and it is largely dependent on the G-protein coupled receptors, namely the P2Y1 receptor that 
is coupled to Gαq, and the P2Y12 receptor that is coupled to Gαi11-12  
TxA2 is a prostaglandin product of arachidonic acid and a potent platelet activator13. The 
production of TxA2 begins with the release of arachidonic acid from membrane phospholipids 
or DAG that is activated by calcium-sensitive phospholipase A2 (PLA2). Arachidonic acid is 
then converted into prostaglandin H2 by cyclooxygenase (COX) and successively into TxA2 
by thromboxane synthase. TxA2 is released by activated platelets and recruits more platelets 
to a site of vessel injury. Released ADP has a similar effect.  Both ADP secretion and TxA2 
release are therefore of great interest in the understanding of positive feedback mechanisms 
on clot development.  
One of the most interesting platelets agonists is collagen as it not only binds to adhesive 
receptors on the platelet plasma membrane14, it also initiates platelet activation through its 
signalling membrane-receptor glycoprotein (GP)VI15. GPVI belongs to the immunoglobulin 
(Ig) superfamily16 and it is constitutively associated with FcRγ, a protein containing an 
immunoreceptor-tyrosine–based activation motif  (ITAM)17 . The early events that follow 
GPVI engagement comprise the activation of Spleen Tyrosine Kinase (Syk)18  through 
phosphorylation or ubiquitination19-20, and Phosphoinositide 3 kinase (PI3K)21 , possibly 
through its regulatory subunit 22. Recently, many studies investigating collagen signalling 
utilized collagen related peptide (CRP) instead of collagen because it specifically binds to 
GPVI therefore allowing for better molecular dissection of the signalling19, 23. αIIbβ3, P2Y1, 
P2Y12, COX, TxA2, Syk, and PI3K are all targets for antiplatelet therapy24 and are part of a 
signalling pathway that is relatively well characterized25.  
 
However the responses to pathway perturbations are not always intuitive, indicating that some 
of the regulatory circuits are still unknown and awaiting discovery. For this reason we have 
determined the sensitivity of fibrinogen binding and ADP secretion after pathway 
perturbation. By considering both the responses simultaneously and by complementing our 
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findings with the relevant literature, we were able to trace a potential wiring diagram that 
links the target proteins, ADP secretion and integrin activation. Such a model, although not 
definitive, facilitates the analysis of the network properties and sets the ground for a 
quantitative study.  
2. Materials and methods 
 
2.1. Materials:  
Thrombin receptor activating peptide (TRAP) was obtained from Bachem (Merseyside, UK). 
Collagen–related peptide (CRP-X) used in these studies was obtained from the laboratory of 
Professor Richard Farndale (Cambridge, UK). All other reagents were obtained from Sigma-
Aldridge except the following: Syk inhibitor II (Calbiochem Merk), SQ29548, MRS2395 & 
MRS2179 (Enzo Life Sciences, UK), and tirofiban (Merck Sharp & Dohme Ltd. 
Hertfordshire, UK). Chronolume was obtained from Chronolog (Labmedics Limited, UK) 
and Oregon Green labelled Fibrinogen was obtained from Molecular Probes via Biosciences 
Limited, Ireland.  
 
2.2. Washed Platelet preparation  
Washed platelets (WP) were prepared from donors who gave informed consent. Venous 
blood was drawn into 15% (v/v) of acid-citrate-dextrose (ACD) anticoagulant (38mM citric 
acid anhydrous, 75 mM sodium citrate, 124mM dextrose). Blood was centrifuged at 150 x g 
for 10 minutes and the platelet rich plasma (PRP) was collected. PRP was acidified with ACD 
at pH 6.5 and 1 µM prostaglandin E1 (PGE1) was added. The platelets were pelleted 720 x g 
for 10 minutes and resuspended in buffer (6 mM dextrose, 130 mM NaCl, 9 mM NaHCO3, 10 
mM sodium citrate, 10 mM Tris base, 3mM KCl, 0.81 mM KH2PO4 and 0.9 mM 
MgCl26H2O, pH 7.35) and the concentration adjusted to 3x105 platelets/µl. WP were 
supplemented with 1.8 mM CaCl2 immediately prior to use. 
2.3. ADP release assay 
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Platelet ADP secretion was assessed as previously described26-27. Inhibitors were dispensed in 
a final volume of 10 µl into different wells of a 96-well white plate (Sigma-Aldrich, Ireland) 
and 70 µl of WP were gently pipetted on top. The inhibitors used were Syk inhibitor II (from 
1.37 to 1000 nM), wortmannin (from 0.34 to 250 nM), aspirin (from 1.37 to 100 µM), 
SQ29548 (from 2.194 to 1600 nM), MRS2179 (from 68.5 nM to 50 µM), MRS2395 (from 
68.5 nM to 50 µM), and tirofiban (from 0.685 pM to 0.5 nM).  
 
Platelets were incubated in the presence or absence of incremental doses of inhibitors for 15 
minutes at 37°C. CRP (1 µg/ml; from Dr Richard Farndale, Cambridge, UK) or TRAP 
(10µM; Bachem, UK) was then added and allowed to activate platelets for 10 minutes at 
37°C. Finally, 10 µl of the detection reagent Chronolume (Chronolog; Labmedics Limited, 
UK) were dispensed in the wells and the sample luminescence was detected using a Wallac 
1420 Multilabel Counter (Perkin Elmer). For the inhibitor studies shown in figure 2, data was 
obtained from 6 independent donors. All inhibitors were tested on the same 6 donors in 
parallel. Data were expressed as a percentage of a maximal response, defined as the response 
to CRP or TRAP in the absence of any inhibitor. Values obtained in the presence of inhibitors 
were subtracted from this 100% response.  Data presented represent mean ± sem for 6 
independent donors.  
2.4. Flow cytometry of fibrinogen binding  
Washed platelet aliquots (20 µl) were dispensed in 15mm plastic tubes and pre-treated with 
increasing concentrations of the various inhibitors for 15 minutes in a final volume of 90 µl. 
Oregon Green labelled Fibrinogen (10 µl, to a final concentration of  0.15 mg/ml, Biosciences 
Limited, Ireland) and the agonist  were then added and the reaction was allowed to proceed 
for 10 minutes. The assay was terminated by the addition of 1ml of cold buffer. Platelet-
associated fluorescence was estimated using a FACSCalibur flow cytometer. Assays with 
inhibitors were performed in parallel with the ADP secretion assays (above) on the same 6 
independent donors. Data were expressed as a percentage of a maximal response, defined as 
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the response to CRP or TRAP in the absence of any inhibitor. Values obtained in the presence 
of inhibitors were subtracted from this 100% response.   
2.5. Statistical Analysis 
Standard errors were determined using Instat, the statistical package associated with 
GraphPad Prism 4 for Windows. Statistical changes in tirofiban-treated platelets were 
determined performing paired t-tests for each dose, with R software for statistical computing 
and graphics. R is a computer language and environment for data handling and analysis and it 
was used here in order to calculate the level of significance of the observations regarding the 
tirofiban.  
 
3. Results 
3.1 Characterization of Assay parameters in human Platelets 
Collagen related peptide (CRP) was chosen as an agonist for this study as it binds to the 
collagen receptor glycoprotein (GP) VI, but not to the integrin α2β1. To identify a useful dose 
of CRP peptide to use in our studies, we examined the effects of increasing doses of CRP 
peptide on platelet ADP secretion and fibrinogen binding assays. CRP induces a dose-
dependent response that is saturated at concentrations in excess of 2 µg/ml in both assays.  A 
dose of 1µg/ml CRP was chosen for all future studies as it consistently caused a submaximal 
response (Figure 1). A dose of agonist that induced an 80% maximal response was considered 
optimal for these studies as it would permit the identification of both inhibitory and activating 
agents in our assays. Moreover, this dose of CRP is capable of causing a response that is 
equivalent to 62% of the response to a maximal dose (8µM) of TRAP peptide in ADP-
secretion assays and 81% of the maximal TRAP induced fibrinogen-binding response (8µM; 
Figure 1D). Thus, although the dose of CRP used in our study might appear low, we establish 
that this batch of CRP-X peptide is highly potent and that the dose chosen for our study 
causes a substantial and equivalent activation of platelets in both assays used in our study. 
This dose of CRP is capable of inducing platelet aggregation (data not shown) as expected. 
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However, because platelet aggregation responses is not a sensitive measure of platelet 
response 28 and because we wished to examine small increments in response associated with 
specific inhibitors, we opted to examine the related index of fibrinogen binding in our assays.  
 
3.2 Effect of pharmacological inhibitors upon CRP-induced fibrinogen binding and 
ADP release.  
To determine the role of intracellular pathways in the regulation of CRP-induced integrin 
activation and ADP secretion we investigated the effect of the selective inhibitors Syk 
inhibitor II29, wortmannin30, aspirin31, SQ2954832, MRS217933, MRS239534. It is known that 
Syk is a central component of the intracellular signalling cascade elicited by GPVI 
engagement19. Syk inhibitor-II retains its selectivity for Syk at doses up to 1 µM (doses higher 
than 1 µM were not investigated due to the documented lack of selectivity29). Increasing 
doses of Syk inhibitor-II produce similar inhibition profiles in ADP secretion and integrin 
activation, consistent with a role of Syk as a crucial check-valve in the control of the two 
activation endpoints under study (Fig. 2A).  
Wortmannin inhibits mammalian class 1a, class 1b and class 3 PI 3-kinases (PI3Ks) at low-
nanomolar concentrations by covalently binding to a catalytically relevant lysine residue in 
the p110 subunit30. At concentrations greater than 100 nM, wortmannin will inhibit some 
isoforms of PI 4-kinase35 and phospholipase A236; therefore, only one dose greater than 100 
nM was used in our studies in order to maintain the specificity for PI3K. As illustrated in Fig. 
2B, the CRP-induced fibrinogen binding is only partially inhibited by the inhibition of PI3K 
activity, whereas the secretion of ADP is completely abolished at concentrations of 100 nM. 
In both of these assays, it is clear that the PI3K inhibitor has reached its maximum effect, as 
the dose-inhibition curves reach a plateau. Moreover, the shape of these dose-inhibition 
curves conforms to classical inhibition criteria. Thus, the range of drug doses required to 
induce an inhibition of the response of between 10 and 90% was approximately 80 fold and 
Hill co-efficients were close to 1.0. Aspirin (Fig. 2C) and SQ29548 (Fig. 2D) were used in 
order to evaluate the contribution of thromboxane signalling in CRP-stimulated activation of 
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platelets. The first inhibits the intracellular production of thromboxane by inhibition of 
COX31, whereas the latter blocks the thromboxane receptor on the cell membrane32. Both 
inhibitors showed only a mild inhibition of fibrinogen-binding to CRP-activated platelets. 
Due to the high variability observed in SQ29548-treated platelets (Fig. 2D), it is difficult to 
draw reliable conclusions. The inhibition profile of aspirin-treated platelets, on the other 
hand, with its low variability (Fig. 2C), allows us to affirm that thromboxane signalling is 
likely to be responsible for 20% of the fibrinogen binding response and for the 40% of ADP 
secretion. 
Furthermore, we observed that the antagonism of purinergic P2Y1 and P2Y12 receptors, with 
MRS2179 and MRS2395 respectively, has little effect at any dose except the highest dose 
tested (Fig. 2E and 2F), suggesting that GPVI-induced activation is mostly independent of 
single ADP receptors. It seems noteworthy that the pharmacological inhibition of both the 
receptors at higher doses has a more prominent effect on the secretory response than on the 
fibrinogen binding response. However, at lower doses, P2Y12 inhibitor appears to slightly 
promote secretion.  
 
3.3. Tirofiban increases the secretion of ADP at low doses  
Tirofiban is an RGD-mimetic37 that binds integrin αIIbβ338 and hinders the binding of 
fibrinogen. When washed platelets were incubated with this integrin inhibitor, we observed 
that doses that were able to almost ablate the binding of fibrinogen were in fact enhancing the 
secretion of ADP in response to CRP-activation (Fig. 3). We also used thrombin receptor 
activating peptide (TRAP; 8µM) as an agonist and observed a similar phenomenon (Fig. 3B). 
The significance was verified by Student t-test.  
4. Discussion  
In this present study, our data demonstrate a differential effect of a range of clinically-
relevant inhibitors on collagen-induced ADP secretion and fibrinogen binding in human 
platelets. Thus, fibrinogen binding is inhibited by the αIIbβ3-inhibitor, tirofiban and by Syk 
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Inhibitor II, but is only partially inhibited by wortmannin or aspirin and is unaffected by the 
ADP receptor antagonists MRS2179 and MRS2395. In contrast, ADP secretion is fully 
inhibited by Syk inhibitor II and by wortmannin, is partially inhibited by aspirin and only 
affected by high concentrations of the ADP-receptor antagonists. Surprisingly, ADP secretion 
was substantially and significantly enhanced by the αIIbβ3-antagonist, tirofiban suggesting 
the presence of a biochemical feedback link between integrin activation and platelet granule 
secretion. We attempted to construct a novel model of platelet signaling pathways that 
incorporates this new information.  
 
Several studies contributed to the development of current models of the early events in 
collagen signalling (as schematized on the left of Fig. 4, black links)25 . It is known that, upon 
GPVI engagement, the signal propagates from FcRγ to Fyn/Lyn, Syk, PI3K and finally 
PLCγ2. The membrane proximal steps of ADP signalling and the release of TxA2 are also 
known, at least in some aspects. Likewise, the inside-out integrin signalling was studied 
extensively and a model was developed that accounts for a number of observations8. 
However, it was not known, to date, how these signalling modules integrated to produce the 
overall responses observed in activated platelets. The model hereby presented (Fig. 4), while 
partial, accomplishes the purpose of demonstrating the platelet signalling in an integrative 
manner, which we believe will prove valuable to the advancement of platelet systems 
biology. Extensive literature mining was performed in order to contextualize our results 
though some of the important nodes were not analyzed due to space constraints. Of note, the 
contribution of the various PKC isoforms and the details of cytoskeletal regulation, although 
of undeniable importance, were omitted.  
Our results suggest the existence of three novel functional links depicted in green, red and 
blue in Fig. 4. The green link represents a functional interaction that connects Syk to integrin 
activation without passing through the kinase activity of PI3K. Fig. 2A and 2B indicate that 
Syk is necessary for both responses, as previously described18, and that the catalytic function 
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of PI3K has a non-redundant role in ADP secretion while being only partially responsible for 
integrin activation. Composing these two observations, we hypothesized that the activation 
signal brought about by phosphorylated Syk is not fully absorbed by the catalytic activity of 
PI3K, thus implying a branching of the signalling route upstream of PI3K. PI3Ks are 
heterodimers comprised of a catalytic (p110) and a regulatory subunit (p85) that were both 
reported to be involved in collagen signalling39-40. Wortmannin only inhibits kinase activity30 
therefore a role for p85 cannot be excluded. The residual fibrinogen binding function 
observed in wortmannin-treated platelets is to be considered independent from the kinase 
activity of PI3K and from the signalling downstream of ADP receptors as ADP secretion is 
abolished. Since the nature of Syk-to-αIIbβ3 link was not investigated, a black-box was 
interposed which will be empty in case the link is direct. This observation agrees, to a large 
extent, with data obtained from p85α deficient mice which used platelet aggregation rather 
than fibrinogen binding to illustrate an inhibition of platelet function. Platelets treated with 
wortmannin may be expected to recapitulate the phenotype of the p85α-/- platelets as these 
platelets where also shown to down-regulate the expression of class AI p110, the catalytic 
subunits of PI3K. The authors showed an approximate 40% to 60% reduction of platelet 
aggregation in response to high-dose CRP (2-5 µg/ml) but the complete absence of 
aggregation in response to low-dose CRP (1µg) (38). However, batch to batch variability in 
CRP peptides necessitates bioassay of each separate batch to establish potency (Prof. R. 
Farndale; personal communication). Our data demonstrate that the batch of CRP that we use 
is highly potent (Fig 1A&B) and that a dose of 1µg/ml causes an 80% maximal response. Our 
results therefore are consistent with the reduction observed in p85α-/- platelets stimulated 
with higher doses of CRP (2-5 µg/ml), rather than with the complete ablation of response in 
platelets stimulated with low-dose CRP, likely because our batch was very potent (Fig.1). In 
any case, the parallel between the phenotype of p85α knockout mice platelets to that of 
wortmannin-inhibited human platelets should not be over-estimated, as the two systems are 
very different, not only for species-dependent issues, but also because the altered expression 
profiles of p110 subunits confounds the interpretation of the p85α-depleted phenotype41-42. 
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Thus, we can state that a PI3K-independent pathway contributes to integrin activation and 
fibrinogen binding in human platelets.  
 
The red link is suggested by Fig. 1F, where high doses of MRS2395 cause an inhibition of 
ADP secretion. This would imply that platelet-released ADP augments dense granule 
secretion in a positive feedback loop. In contrast, low doses of MR2395 seem to slightly, but 
significantly (P<0.01) augment ADP secretion.  This might suggest that a concentration-
sensing mechanism in place that facilitates secretion when extracellular ADP levels are 
perceived to be low, but which inhibits excessive secretion when plasma ADP levels are high. 
Thus, such mechanism results in positive signalling only when a certain concentration 
threshold is exceeded. Such a mechanism would guarantee a controlled release of ADP.  
 
Finally, the blue link refers to the finding that, strikingly, doses of tirofiban that were able to 
almost fully ablate the binding of fibrinogen were observed to significantly enhance ADP 
secretion (Fig. 3). The present model is informed by the finding that tirofiban can behave as a 
partial agonist43-44. Nevertheless, the exact mechanism underlying the phenomenon remains 
elusive. In particular the question is raised whether the clinical adverse effects of RGD-
mimetics could be ascribed to this non-intuitive enhancement of platelet secretion responses. 
Bassler and colleagues45 have demonstrated the capacity for platelet-released ADP to 
‘prestimulate’ platelets in patients being treated with integrin antagonists. Our data confirm 
the capacity for one such RGD-mimetic, Tirofiban, to simultaneously inhibit fibrinogen 
binding while enhancing the platelet secretory response. Our data provides evidence 
suggesting an important role for this previously unknown (or unappreciated) component of 
the platelet signal pathway. In support of this a recent paper demonstrates the capacity of 
RGD and its mimetics, lotrafiban and tirofiban, to enhance dense-granule secretion in 
platelets46. These authors similarly argued that this response may assist in understanding why 
integrin antagonists failed in clinical trials47. This paradoxical activation of platelet secretion 
will exert both specific and non-specific effects on platelet function through specific 
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competitive platelet activation via ADP and non-specific effects exerted by other agents 
released simultaneously from platelet granules, respectively.  
 
Thus, there appears to be a feedback loop between the integrin ADP-secretion which is 
perturbed by pre-treatment of platelets with ligand mimetic αIIbβ3 inhibitors. Understanding 
this pathway will be essential for the design of future anti-platelet therapies for the treatment 
and prevention of thrombosis. 
 
Furthermore, some concluding remarks can be formulated about the results and the model. 
One general consideration that our results suggest is that the secretion of ADP appears to be 
more sensitive to inhibition as compared to the fibrinogen binding (Fig. 2). This is not 
surprising considering that, unlike adhesion, ADP secretion is an amplification response 
hence the necessity for a tighter control. Secondly, from our literature survey, especially 
regarding ADP and TxA2 receptors48-50, it clearly emerged that coincidence detection is a 
design principle largely employed in this platelet signalling network. Lastly, the diagram in 
Fig. 4 displays numerous feed-forward loops and a relative paucity of negative regulation 
mechanisms. This might be an artifact caused by the scarcity of studies about negative 
regulation due to the focus on discovery of small molecule inhibitors of platelet aggregation. 
We anticipate that the full wiring diagram will have more negative regulators and that further 
investigation will aim at determining the weight of the links.  
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7. Figure Legends 
Fig. 1.  Effect of different doses of CRP on ADP release and fibrinogen binding. A and B: 
Platelets were stimulated with increasing doses of CRP for 3 minutes and representative dose-
response profiles are shown for ADP release (A) and for Oregon-Green Fibrinogen binding 
(B) (data represents one donor and error bars refer to the 3 replicates). C and D: Activation 
caused by CRP (1 µg/ml) is compared to activation caused by TRAP 8 µM and the results 
shown refer to 4 donors (error bars represent S.E.M). E, A representative image showing 
increased fibrinogen binding in resting platelets (Blue) or platelets activated for 3 minutes 
with TRAP (8 µM; Green) or CRP (1µg/ml;Pink) as determined by FACS analysis. 
 
 
 
Fig 2. Effect of Syk, PI3K, COX, TXA2R, P2Y1 and P2Y12 inhibition upon fibrinogen 
binding and ADP release in CRP-stimulated human platelets. Platelets were pre-treated 
with the indicated concentration of inhibitors. Following stimulation with CRP (1µg/ml), 
platelets were assayed for fibrinogen binding () and for ADP secretion (). Results were 
normalized for each donor relative to the response seen in unstimulated platelets (0%) and the 
maximal response seen in CRP-stimulated platelets (100%) in the absence of any inhibitors. 
Data points represent the means ± S.E.M. of six independent experiments.  
 
Fig.3. Effect of tirofiban on fibrinogen binding and ADP release. Platelets were pre-
treated with the indicated concentration of tirofiban and then stimulated with 1µg/ml CRP 
(panel A) or 8µM TRAP (panel B). Results were normalized for each donor as explained in 
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figure legend for Fig. 2. Data points represent the means ± S.E.M. of six (panel A) or four 
(panel B) independent experiments where * P < 0.001. 
 
Fig. 4. Platelet signalling. The diagram schematizes some of the functional interactions 
within the GPVI signalling network. The star (*) indicates that the protein is in its active state. 
The red inhibition symbols correspond to the proteins that were inhibited. The circles indicate 
that the link has a positive effect, either of stimulation or catalysis, on the transition (grey 
arrow) that it refers too. The black boxes represent a set of functional interactions that are 
unknown or only partially known and they can be empty in case the interaction is direct. 
Black lines: interactions inferred from previous literature and this study. Green, red and blue 
lines: inferred from this study.  
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Figure 2.  
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Figure 3 
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Figure 4 
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